You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine receptor motif domains (TIGIT)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Malignancies Trial in Beijing (IBI939, IBI939+ Sintilimab)

Active, not recruiting
  • Advanced Malignancies
  • Beijing, China
    Peking University Cancer Hospital & Institute
Oct 4, 2022

Advanced Upper Gastrointestinal Tract Adenocarcinoma Trial in United States (Zimberelimab, Domvanalimab, Nivolumab)

Recruiting
  • Advanced Upper Gastrointestinal Tract Adenocarcinoma
  • Hot Springs, Arkansas
  • +11 more
Dec 6, 2022

Melanoma Trial in Worldwide (Pembrolizumab, Quavonlimab, Vibostolimab)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +4 more
  • Los Angeles, California
  • +34 more
Jan 25, 2023

Advanced Solid Tumours Trial (PM1021, PM8001)

Not yet recruiting
  • Advanced Solid Tumours
  • PM1021, PM8001
  • (no location specified)
Sep 12, 2022

Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, V937)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +5 more
  • Los Angeles, California
  • +28 more
Jan 25, 2023

Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab)

Recruiting
  • Melanoma
  • Pembrolizumab
  • +5 more
  • Los Angeles, California
  • +39 more
Jan 25, 2023

Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +5 more
  • Jacksonville, Florida
  • +2 more
Oct 21, 2022

Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Seattle (SC-DARIC33)

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • SC-DARIC33
  • Seattle, Washington
    Seattle Children's Hospital
Sep 6, 2022

Head and Neck Tumors, MSI-H Cancer, Melanoma Trial (Tiragolumab and atezolizumab)

Not yet recruiting
  • Head and Neck Neoplasms
  • +2 more
  • Tiragolumab and atezolizumab
  • (no location specified)
Aug 1, 2022

Melanoma Trial in Nedlands, Haifa, Jerusalem (Pembrolizumab/Vibostolimab, Pembrolizumab)

Recruiting
  • Melanoma
  • Pembrolizumab/Vibostolimab
  • Pembrolizumab
  • Nedlands, Western Australia, Australia
  • +2 more
Jan 31, 2023

TIGIT in Patients With Chronic Myeloid Leukemia

Not yet recruiting
  • Chronic Myeloid Leukemia
  • flow cytometry test
  • (no location specified)
Mar 25, 2021

B-cell Non Hodgkin Lymphoma Trial in Augsburg, Cologne, Hamburg (MB-CART2019.1 Dose level 1, MB-CART2019.1 Dose level 2)

Active, not recruiting
  • B-cell Non Hodgkin Lymphoma
  • MB-CART2019.1 Dose level 1
  • MB-CART2019.1 Dose level 2
  • Augsburg, Bavaria, Germany
  • +2 more
Jun 13, 2022

Pre-Eclampsia Trial (real time PCR)

Not yet recruiting
  • Pre-Eclampsia
  • real time PCR
  • (no location specified)
Mar 22, 2022

Lymphoma Trial in Seattle (biological, other, procedure)

Not yet recruiting
  • Lymphoma
  • Immune Globulin Infusion (Human), 10% Solution
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 21, 2023

Type 1 Diabetes Trial in United States (Siplizumab)

Not yet recruiting
  • Type 1 Diabetes Mellitus
  • Birmingham, Alabama
  • +19 more
Jan 25, 2023

Breast Cancer Trial in Philadelphia (huCART-meso cells, Mesothelin Expression Testing)

Not yet recruiting
  • Breast Cancer
  • huCART-meso cells
  • Mesothelin Expression Testing
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jan 5, 2023

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

T-ALL Trial in Suzhou (T cell injection targeting CD7 chimeric antigen receptor)

Recruiting
  • T-ALL
  • T cell injection targeting CD7 chimeric antigen receptor
  • Suzhou, Jiangsu, China
    The First Affiliared Hospital Of SOOCHOW University
Mar 3, 2021

Multiple Sclerosis COVID-19/Vaccination Treated With Ofatumumab

Completed
  • Multiple Sclerosis
    • East Hanover, New Jersey
      Novartis
    Jul 14, 2023

    Multiple Myeloma Trial in Beijing, Guangzhou, Shanghai (TQB2934 injection)

    Not yet recruiting
    • Multiple Myeloma
    • TQB2934 injection
    • Beijing, Beijing, China
    • +2 more
    Dec 8, 2022

    Multiple Myeloma, Refractory Trial in Washington, Hackensack, Neptune (Pembrolizumab, Belantamab mafodotin, Dexamethasone)

    Not yet recruiting
    • Multiple Myeloma, Refractory
    • Washington, District of Columbia
    • +2 more
    Aug 5, 2022

    HIV Infection Primary Trial in Badalona (Dasatinib 70 mg, Placebo)

    Not yet recruiting
    • HIV Infection Primary
    • Dasatinib 70 mg
    • Placebo
    • Badalona, Barcelona, Spain
      Hospital Universitari Germans Trias i Pujol
    Mar 9, 2023

    Advanced Hepatocellular Carcinoma Trial in Guangzhou (Bifidobacterium Bifidum Oral Product)

    Recruiting
    • Advanced Hepatocellular Carcinoma
    • Bifidobacterium Bifidum Oral Product
    • Guangzhou, Guangdong, China
      The Third Affiliated Hospital of Sun Yat-Sen University
    Nov 16, 2022

    Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Trial in United States (pepinemab + pembrolizumab)

    Recruiting
    • Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
    • pepinemab + pembrolizumab
    • Springdale, Arkansas
    • +17 more
    Dec 7, 2022

    Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle

    Terminated
    Has Results
    • Hematopoietic and Lymphoid Cell Neoplasm
    • +12 more
    • Laboratory Biomarker Analysis
    • ROR1 CAR-specific Autologous T-Lymphocytes
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 11, 2022